NIH-Funded Study Finds Critical Population Adheres to PrEP with Coordinated Care


New findings suggest that black men who have sex with men (BMSM) with access to a novel coordinated care program can adhere to pre-exposure prophylaxis (PrEP), a medication regimen that helps prevent HIV infection in uninfected individuals. Researchers reported their results today at a press conference at the Conference on Retroviruses and Opportunistic Infections (CROI)…

NIH’s Dr. Carl Dieffenbach Shares Highlights from Start of CROI 2016 (Video)


After the first full day of sessions at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston yesterday, February 23, we caught up with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), to get his take on some of the key highlights of…

Tremendous Progress Made in HIV, but Serious Disparities Remain


Summary: Data released at this year’s CROI meeting demonstrates need for continued focus and action. This week, I’m in Boston for the annual Conference on Retroviruses and Opportunistic Infections (CROI). It’s one of the premier scientific meetings where we hear the latest research in HIV prevention and treatment. Last year, for example, researchers presented undeniable…

NIH-Funded Study Finds Effect of PrEP on Bone Density is Reversible

nih logo

The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. PrEP is an HIV prevention strategy in which at-risk HIV-negative…

Half of black gay men and a quarter of Latino gay men projected to be diagnosed within their lifetime

CDC Logo

If current HIV diagnoses rates persist, about 1 in 2 black men who have sex with men (MSM) and 1 in 4 Latino MSM in the United States will be diagnosed with HIV during their lifetime, according to a new analysis by researchers at the Centers for Disease Control and Prevention (CDC). The study, presented…

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial

Woman holding the dapivirine vaginal ring tested in the NIH-funded ASPIRE study.
Credit: International Partnership for Microbicides

NIH-Funded Study Finds Protective Effect Strongest in Women over Age 25 A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by…

Scientific Advances in HIV and HCV To Be Examined Next Week at CROI 2016


The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week in Boston, and will be there. This annual scientific meeting brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related…

Califf, FDA top officials call for sweeping review of agency opioids policies


Editor’s Note: Reducing opioid misuse not only reduces deaths from overdose but is also key to reducing new HIV and viral hepatitis infections among persons who inject drugs. For more on the link between opioid misuse, HIV and viral hepatitis, see this CDC report. In response to the opioid abuse epidemic, today Dr. Robert Califf, the…